SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (570)11/5/2003 12:50:49 AM
From: Jibacoa  Read Replies (1) of 3661
 
O.T.

I just talked to a source with a copy of the JAMA article mentioned below involving Esperion Therapeutics' (ESPR-Nasdaq) arterial plaque-reducing drug ETC216. And yes, the data is negative.

That's not the opinion of Mathew Harper on Forbes.

Steven Nissen, the Cleveland Clinic cardiologist who led the trial points out that patients received the drug for only five weeks and the 4.2% reduction they saw "is huge," according to him. When they initially designed the trial, he had estimated a 3% reduction. And that was optimistic.

forbes.com

BTW I stll remember the article by Cook et al. on the Am.J.of Med. many years ago about the results on rabbits with L-arginine. They were impressive enough for me to take some L-arginine along with Vitamin E ounce in a while.<g>(Especially since L-arginine is a precursor of NO or EDRF.)

The article from Cook et al. if I remember correctly was from Stanford. A more recent one from Harvard by Girerd (I don't know if the Cook collaborator is the same.<g>)seems to also show that exogenous L-arginine normalizes the endothelium-dependent vasodilation of hind limb resistance vessels in cholesterol-fed rabbits.(Hypercholesterolemia is known to reverse the acetylcholine vasodilation.)

ncbi.nlm.nih.gov

Bernard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News